FDA Approves Sorilux for Adolescent Plaque Psoriasis
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
The US Food and Drug Administration (FDA) has approved SORILUX (calcipotriene) Foam, 0.005% in adolescents.
As GLP-1 medications drive significant weight loss for more patients, aesthetic providers are seeing a rise in facial hollowing, skin laxity, and other changes associated with GLP-1 face. Anthony Rossi, MD, discusses the structural aging patterns highlighted in a recent ASJ Open Forum study and how clinicians are approaching treatment with a conservative, multimodal strategy.